Ceapro Inc V.CZO

Category breaker

[prophetoffactz]

While the yeast beta glucan immune booster market may be $1 billion the larger immune booster market is $20 billion/+. CZO can transform the yeast beta glucan category given its uniqueness. 

1) 5X more binding affinity with dectin-1 in human cell lines suggesting that it may be multi-fold more potent and require a fraction of the dose.
2) Eliminates impurities creating the potential new gold standard for purity/safety/tolerability.
3) It is small enough to be inhalable unlike other beta glucan which could be positive for fighting respiratory pathogens.
4) It is small enough to be swallowed by macrophages creating a potential Trojan Horse.
6) It can be blended with other substances like alginate ot oat beta glucan to enhance performance.
7) It can be impregnated with other bioactives to complement immune activation. 

To optimally participate in partnerships CZO needs capital and human resources. The merger with AEZS adds capital and human resources as PGX is expected to reach commercial-scale production with Natex in about 6 months and the point of decision concerning mass industrialization. The 5X scale-up expected to be commissioned within about 30 days was also expected to allow potential partners to work with PGX material for formulation and testing, etc. We are at the goal line. NASDAQ.

[Tencents]

If any of these elements can be translated into a marketable product it is probably in 10 to 15 years down the road depending on segment for approvals and product positioning  the ceo indicated 7 years for a first revenue Brand marketing per product  is today estimated at nearly 100 m $ to create awareness - General Mills - and others  and these possible markets have enormous

[prophetoffactz]

Tencents, "If any of these elements can be translated into a marketable product it is probably in 10 to 15 years down the road depending on segment for approvals and product positioning the ceo indicated 7 years for a first revenue" The truth: "Depending on the successful scale up of PGX technology and approval from health authorities, this product could be offered as an

[Tencents]

Yes offered to potentiel partners who would evaluate the potentiel and if positive plan the approvals and road to market  but not marketed to end users thats years away 

[prophetoffactz]

No. The 50L facility expected to be commissioned in the next 30 days will provide material for potential partners, formulation and testing. The 100L facility expected to be commissioned in Q3 is a small-scale commercial facility that lets CZO sell product. In the following video at 23:40 Gilles notes the 50L facility will provide clinical study material and the 100L facility is small-scale

[Tencents]

Yes to start marketing - to potentiel distributors to allow them test on market positioning / formulation etc  thats years away from selling a product in meaningful numbers  the cost and effort of mass sales and marketing is enormous lets say there are 3 products aimed at different segments - thats about 250 m $ of brand building and several years of effort